Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Some statistical issues in HIV vaccine trials

W N Rida1, D N Lawrence

  • 1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

Statistics in Medicine
|October 15, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AIDS-specific screening and therapy still elusive.

Immunology today·2014
Same author

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

Vaccine·2003
Same author

Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations.

Statistics in medicine·1998
Same author

HIV vaccines.

Lancet (London, England)·1997
Same author

Assessing the effect of HIV vaccination on infectiousness.

Statistics in medicine·1996
Same author

Preparation for HIV vaccine efficacy trials.

Antibiotics and chemotherapy·1996

Conducting prophylactic HIV vaccine efficacy trials presents significant recruitment and statistical challenges. This research outlines key considerations for trial design, analysis, and interpretation, including endpoints and secondary objectives.

Area of Science:

  • Clinical Trials
  • Vaccinology
  • Epidemiology

Background:

  • Prophylactic human immunodeficiency virus (HIV) vaccine efficacy trials are exceptionally complex.
  • Challenges include recruiting and retaining high-risk populations and addressing intricate statistical issues.

Purpose of the Study:

  • To describe general features of HIV vaccine efficacy trials.
  • To discuss statistical challenges in trial design, conduct, analysis, and interpretation.
  • To examine secondary objectives and novel trial designs.

Main Methods:

  • Review of general features for efficacy trials.
  • Discussion of primary endpoints and vaccine efficacy estimation.
  • Examination of secondary objectives, including correlates of immunity and biological markers.

Related Experiment Videos

  • Analysis of trial designs for multiple vaccine candidates or prevention strategies.

    • Main Results:

    • Efficacy trials require careful selection of primary endpoints and robust statistical methods for testing and estimation.
    • Secondary objectives provide crucial insights into correlates of protection, impact of viral genetic variation, and disease progression using markers like viral load and CD4+ cell counts.
    • Novel trial designs can efficiently evaluate multiple HIV prevention strategies concurrently.

    Conclusions:

    • HIV vaccine efficacy trials necessitate meticulous planning regarding statistical methodologies and participant recruitment.
    • Secondary objectives and biological markers are vital for a comprehensive understanding of vaccine performance and impact.
    • Innovative trial designs can optimize the evaluation of diverse HIV prevention interventions.